Renal Toxicity following Zoledronic Acid Reversed with Ibandronate in a Prostate Cancer Patient with Bone Metastases

Publisher： Karger

E-ISSN： 1423-0399|80|4|448-450

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.80, Iss.4, 2008-06, pp. : 448-450

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of Bone Metastases in Lung Cancer: The Actual Role of Zoledronic Acid

By  

Reviews on Recent Clinical Trials, Vol. 4, Iss. 3, 2009-09 ,pp. : 205-211

Bentham Science Publishers

Access to resources Recommend Favorite

Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis

By Hatoum Hind T.   Lin Swu-Jane   Guo Amy   Lipton Allan   Smith Matthew R.  

Current Medical Research and Opinion, Vol. 27, Iss. 1, 2011-01 ,pp. : 55-62

Informa Healthcare

Access to resources Recommend Favorite

Well-Differentiated Hand Liposarcoma with Bone Metastases Treated Successfully with Zoledronic Acid

By  

Oncology Research and Treatment, Vol. 34, Iss. 12, 2011-11 ,pp. : 706-709

Karger

Access to resources Recommend Favorite

Bone metastases in prostate cancer: which scan?

By  

BJU INTERNATIONAL, Vol. 114, Iss. 6, 2014-12 ,pp. : 792-793

John Wiley & Sons Inc

Access to resources Recommend Favorite

Titration of Dosage for the Protective Effect of Zoledronic Acid on Bone Loss in Patients Submitted to Androgen Deprivation Therapy due to Prostate Cancer: A Prospective Open-Label Study

By  

Urologia Internationalis, Vol. 85, Iss. 2, 2010-07 ,pp. : 180-185

Karger

Access to resources Recommend Favorite